Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: lamivudine

« Back to Dashboard

Lamivudine is the generic ingredient in five branded drugs marketed by Viiv Hlthcare, Glaxosmithkline, Silarx Pharms Inc, Apotex, Apotex Inc, Aurobindo Pharma Ltd, Hetero Labs Ltd V, Lupin Ltd, Mylan Pharms Inc, and Teva Pharms, and is included in sixteen NDAs. There are three patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

There are twenty-four drug master file entries for lamivudine. Nine suppliers are listed for this compound. There are fifty-nine tentative approvals for this compound.

Summary for Generic Name: lamivudine

Tradenames:5
Patents:3
Applicants:10
NDAs:16
Drug Master File Entries: see list24
Suppliers: see list9
Therapeutic Class:Antivirals

Tentative approvals for LAMIVUDINE

Applicant Application No. Form Dosage
<disabled><disabled>TABLET; ORAL150MG; 300MG; 200MG
<disabled><disabled>TABLET; ORAL150MG; 300MG; 200MG
<disabled><disabled>TABLET; ORAL150MG; 300MG; 600MG

Clinical Trials for: lamivudine

Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa
Status: Completed Condition: Human Immunodeficiency Virus

Pharmacokinetics of Lamivudine at Two Different Doses
Status: Completed Condition: HIV Infections

Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load
Status: Active, not recruiting Condition: Hepatitis B, Chronic

Comparison Between Lamivudine and Entecavir Treatment in Patients
Status: Recruiting Condition: Chronic Hepatitis B

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets
Status: Completed Condition: Healthy Subjects; Infection, Human Immunodeficiency Virus

Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects
Status: Completed Condition: Healthy Volunteers

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare
COMBIVIR
lamivudine; zidovudine
TABLET;ORAL020857Sep 26, 1997RXYes5,905,082*PED<disabled>Y<disabled>
Teva Pharms
LAMIVUDINE AND ZIDOVUDINE
lamivudine; zidovudine
TABLET;ORAL079081May 25, 2011RXNo<disabled><disabled>
Silarx Pharms Inc
LAMIVUDINE
lamivudine
SOLUTION;ORAL203564Oct 31, 2014RXNo<disabled><disabled>
Aurobindo Pharma Ltd
LAMIVUDINE
lamivudine
TABLET;ORAL202032Nov 17, 2011RXNo<disabled><disabled>
Viiv Hlthcare
EPIVIR
lamivudine
TABLET;ORAL020564Jun 24, 2002RXYes5,905,082*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc